Redhill Biopharma
RDHL
$0.43
Share price
2.22%
Change (1 day)
-81.23%
Change (1 year)
Categories
Redhill Biopharma (RDHL) - P/B ratio
P/B ratio as of April 2024 : 3.95
According to Redhill Biopharma's latest financial reports the company has a price-to-book ratio of 3.95.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Redhill Biopharma - P/B ratio (from 2013 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 8.28 | -3230.24% |
| 2022-12-31 | -0.2644 | -101.74% |
| 2021-12-31 | 15.2 | -30.66% |
| 2020-12-31 | 22.0 | 515.72% |
| 2019-12-31 | 3.57 | 16% |
| 2018-12-31 | 3.08 | 26.77% |
| 2017-12-31 | 2.43 | -14.74% |
| 2016-12-31 | 2.85 | 4.42% |
| 2015-12-31 | 2.73 | -41.82% |
| 2014-12-31 | 4.68 | -26.5% |
| 2013-12-31 | 6.37 | |
| 2012-12-31 | N/A | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 1.49 | -62.21% | 🇫🇷 France |
 Merck MRK | 8.83 | 123.30% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.16 | 30.61% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 1.92 | -51.32% | 🇮🇱 Israel |
 Taro Pharmaceutical TARO | 0.8957 | -77.35% | 🇮🇱 Israel |